Think of Verquvo as a "Niche" Med for Heart Failure
April 2021
You'll hear once-daily vericiguat (Verquvo) is a new add-on for worsening heart failure with reduced ejection fraction (HFrEF).
Vericiguat is the first "soluble guanylate cyclase stimulator" for HFrEF. It relaxes blood vessels through the nitric oxide pathway.
Most evidence is in patients already on triple therapy...an ACEI, ARB, or sacubitril/valsartan (Entresto), beta-blocker (carvedilol, etc), AND aldosterone antagonist (spironolactone, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote